British drugmaker
The company will supply at least 400 million doses of the vaccine called AZD1222 and has secured a capacity to manufacture 1 billion doses.
Of the initial supply, 300 million doses will be delivered to
Early stage clinical trials for AZD1222 began in April with over 1,000 healthy volunteers aged 18 to 55, according to AstraZeneca. If results, expected shortly, are positive, it plans late-stage trials "in a number of countries."
"AstraZeneca recognizes that the vaccine may not work but is committed to progressing the clinical program with speed and scaling up manufacturing at risk," the company said in a statement.
For
The funding will cover a late-stage clinical trial with 30,000 participants and a pediatric trial, it said.
According to data released by the
==Kyodo
© Kyodo News International, Inc., source